<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Soluble intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (sICAM-1) is associated with <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and clinical <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the relationship of subclinical <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> with sICAM-1 concentration </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: sICAM-1 concentration was assayed at year 15 of the Coronary Artery Risk Development in Young Adults (CARDIA) Study (black and white men and women, average age 40 years) </plain></SENT>
<SENT sid="3" pm="."><plain>We assessed progression of <z:hpo ids='HP_0001717'>coronary artery calcification</z:hpo> (CAC) through year 20 (n = 2378), and both carotid <z:mp ids='MP_0006135'>artery stenosis</z:mp> (n = 2432) and intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) at year 20 (n = 2240) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Median sICAM-1 was 145.9 μg/L </plain></SENT>
<SENT sid="5" pm="."><plain>Among a subgroup with advanced atherosclerotic plaque (either CAC or stenosis), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> was 0.010 (95% CI 0.003-0.017 mm) higher per SD of sICAM-1 (44 μg/L) in a model adjusted for age, race, sex, clinic, smoking, exercise, body size, education, blood pressure, <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> medication, plasma <z:chebi fb="23" ids="18059">lipids</z:chebi>, and cholesterol-lowering medication </plain></SENT>
<SENT sid="6" pm="."><plain>With the same adjustment, the odds ratio (OR) for the presence of year-20 carotid <z:mp ids='MP_0006135'>artery stenosis</z:mp> per SD of sICAM-1 was 1.12 (95% CI 1.01-1.25, P &lt; 0.04), whereas for occurrence of CAC progression the OR was 1.16 (1.04-1.31, P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>The associations with CAC and <z:hpo ids='HP_0100546'>carotid stenosis</z:hpo> were strongest in the top 20th of the sICAM-1 distribution </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: sICAM-1 concentration may be an early biomarker that indicates changes in the artery wall that accompany <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, as well as the presence of advanced plaque in the coronary and carotid arteries </plain></SENT>
<SENT sid="9" pm="."><plain>This finding holds in people with low total burden of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, decades before the development of clinical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>